Archonc-001
An Open-label, Single-arm, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Efficacy of MTM-H-001 in the Treatment of Adult Participants With Relapsed or Refractory B-cell Malignancies (Archonc-001)
Sponsor study identifier
interventional
69
1 country
1
Study Start
March 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
January 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is an investigator-initiated, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of MTM-H-001 in adult participants with relapsed/refractory (R/R) B-cell malignancies.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 12, 2026
Actual (reported)March 17, 2026
Actual (reported)January 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
June 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Incidence of Dose-Limiting Toxicity (DLT)
Percentage of participants experiencing DLTs
42 days following first dose of MTM-H-001 for each participant
Objective response rate (ORR)
Throughout the study, up to 24 months
Disease control rate (DCR)
Throughout the study, up to 24 months
Part A: Dose Escalation Part, MTM-H-001 Injection, 4 dose groups are planned. The study treatment period includes an induction phase and a maintenance phase. Part B: Dose Expansion Part, MTM-H-001 Injection, 3 dose cohorts are planned. The dose and frequency for each cohort will be determined based on the safety, PK, and PD data of participants from the dose groups in Part A
Each participant receives MTM-H-001 Injection
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Langfang, Hebei, 065000, China
Ning Li, Ph.D
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
First Submitted
March 12, 2026
First Posted
March 17, 2026
Study Start
March 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
January 2028
EstimatedTime to response (TTR)
Throughout the study, up to 24 months
Duration of response (DOR)
Throughout the study, up to 24 months
Event-free survival (EFS)
Throughout the study, up to 24 months
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
March 17, 2026
Record last verified: 2026-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: